DRG Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of prostate cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we forecast the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s prostate cancer forecast will answer the following questions:

How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with prostate cancer per year?

In developing countries, what impact will economic growth and development have on the number of people diagnosed with prostate cancer per year?

How will improvements in survival change the number of people living with a diagnosis of prostate cancer?

How will a decline in the risk of recurrence change the number of people diagnosed with prostate cancer per year?

Of all people with prostate cancer, how many in each of the major mature pharmaceutical markets have been formally diagnosed?

Of all people diagnosed with prostate cancer, how many in each of the major mature pharmaceutical markets are drug-treated?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following prostate cancer patient populations:

Drug-treatable prevalent cases by metastasization status.

Diagnosed incident cases by TNM and risk category.

Diagnosed prevalent cases by drug-treatment potential.

First-line MCRPC DTP treatment subpopulation(s).

Newly diagnosed high/very high risk (hormone-sensitive) DTP treatment subpopulation(s).

First-line MCRPC drug-treatable population.

Prostate cancer biochemically recurrent (hormone-sensitive) drug-treatment opportunities.

Prostate cancer biochemically recurrent incident cases.

Prostate cancer newly diagnosed high/very high risk (hormone-sensitive) drug-treatment opportunities.

Second-line MCRPC DTP subpopulation(s).

… and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Prostate Cancer - Epidemiology - Asia Pacific Data
    • Introduction
      • Key Findings
        • Overview
          • Incidence of Prostate Cancer per Year per 100,000 Males of All Ages in 2017 and 2027
          • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Prostate Cancer over the Next Ten Years
          • Number of Additional Incident Cases of Prostate Cancer Incurred over 2017-2027 in the Countries Under Study due to Trends in Risk
      • Epidemiology Data
      • Methods
        • Lifetime DALYs Gained
        • Diagnosed Incident Cases of Prostate Cancer
        • TNM Stage and NCCN Risk Category
        • Recurrent Incidence
        • Diagnosed Prevalent Cases
        • Drug-Treatable Populations
        • Drug-Treated Populations
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Prostate Cancer
          • Studies Excluded from the Analysis of Prostate Cancer
        • Risk/Protective Factors
          • Risk/Protective Factors for Prostate Cancer
        • Bibliography

    Author(s): Narendra Parihar; Nishant Kumar, MPH

    Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

    His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.

    Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

    His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


    Related Reports

    Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

    Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

    View Details

    Prostate Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)

    The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx fo...

    View Details

    Prostate Cancer | Disease Landscape and Forecast | G7 | 2020

    Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

    View Details

    Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

    Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

    View Details